FLT3 and acute myeloid leukemia: Finally, we compared the efficacy of the non-approved compounds WS6 and ispinesib in bone marrow samples of healthy controls and AML patients, among which four harbored a FLT3-ITD rearrangement and four expressed wildtype FLT3.